Stephen D. Simpson

The FDA's expert panel recommends approval for Exubera.

Among utilities, Suez stands out with strong growth and a respectable dividend.

This large generics company sees better margins and an optimistic outlook.

Although the company takes a long time to reap its cash, a strong market for luxury goods is still at its back.

Incremental progress is still progress.

While many offshore platforms in the Gulf of Mexico took a hard hit from Katrina, the effects should be transient.

What does the damage from Hurricane Katrina spell for those whose business is moving energy around the world?

The company's second-quarter results highlight why a sale may be a good idea.

Navistar has to balance a very cyclical industry with apparently improving fundamentals.

Bio-Reference is a small business with big potential.

The disruptions to the Gulf's energy infrastructure will have far-reaching effects for who knows how long?

Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities.

The effects of Hurricane Katrina will ripple throughout the entire U.S. economy.

Given how little excess refining and energy-handling capacity there is in the United States, we are lucky that Katrina didn't inflict more damage upon these companies.

Meetings this week will give investors a sense of the regulatory climate for drug applications.

This once-hot tech company still has a long way to go to recapture past glories.

Can Arrow overcome capacity constraints and get the top line flying again?

This defense electronics company has now posted four straight quarterly misses.

Despite a poor fourth-quarter outlook, NCI Building looks like it's on solid foundation.

With the rumored Pepsi bid dead for now, can Danone perform on its own merits?